The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
 
Carlotta Antoniotti
No Relationships to Disclose
 
Daniele Rossini
Speakers' Bureau - MSD Oncology
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck; Merck Serono; Merck Serono; MSD Oncology; SERVIER
Research Funding - Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Pierre Fabre
 
Lisa Salvatore
Honoraria - Amgen; AstraZeneca; Bayer; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Bayer; Celgene; Merck Serono; Pierre Fabre; Sanofi; SERVIER
 
Federica Marmorino
No Relationships to Disclose
 
Margherita Ambrosini
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; Mirati Therapeutics; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Maria Bensi
No Relationships to Disclose
 
Roberto Moretto
No Relationships to Disclose
 
Stefano Tamberi
No Relationships to Disclose
 
Ilaria Toma
No Relationships to Disclose
 
Alessandro Passardi
No Relationships to Disclose
 
Maria Caterina De Grandis
No Relationships to Disclose
 
Veronica Conca
No Relationships to Disclose
 
Federica Palermo
No Relationships to Disclose
 
Alessandro Cappetta
No Relationships to Disclose
 
Aurelie Catteau
Employment - Veracyte
Stock and Other Ownership Interests - Veracyte
Travel, Accommodations, Expenses - Veracyte
 
Luca Boni
No Relationships to Disclose
 
Jérôme Galon
Employment - Veracyte
Patents, Royalties, Other Intellectual Property - HalioDx/Veracyte (Inst)
 
Chiara Cremolini
Honoraria - Amgen; Bayer; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; MSD; Nordic Bioscience; Pierre Fabre; Roche
Speakers' Bureau - Merck; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER